View Clinical Trial (Medical Research Study)

A Comparison of Long-acting Injectable Medications for Schizophrenia - NCT01136772-27509(Clinical Trial 652239)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Butner
State:  
NC
Zip Code: 27509
Conditions: Schizophrenia - Schizoaffective Disorder
Purpose: The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).
Study summary: The purpose of this comparative effectiveness research study is to learn more about different medications called antipsychotics that are used to treat schizophrenia or schizoaffective disorder. Specifically, we are looking at long-acting medications that are given by injection every month, instead of being taken by mouth every day. In this multi-site study, we are comparing the risk and benefits of two FDA-approved long-acting injectable medications (paliperidone palmitate and haloperidol decanoate). Study participants with schizophrenia or schizoaffective disorder are expected to benefit from the improved medication schedule. This study aims to enroll 360 individuals with schizophrenia or schizoaffective disorder for whom treatment with a long-acting injectable antipsychotic medication is likely to be helpful. Study participants will be randomly assigned to treatment with either paliperidone palmitate and haloperidol decanoate for up to 24 months. Participants will have an equal chance of being assigned to each medication, however participants will not know which medication they are taking.
Criteria: Inclusion Criteria: - Diagnosis of schizophrenia or schizoaffective disorder as defined by DSM-IV-TR criteria - Age 18-65 years - Capacity to provide informed consent - Patients who are likely to benefit from treatment with long-acting injectable paliperidone palmitate or haloperidol decanoate Exclusion Criteria: - Patients who are currently stable and doing well on an antipsychotic regimen - Patients not expected to benefit from the study medications due to past experience with risperidone, paliperidone or haloperidol - Patients with tardive dyskinesia that is moderate or severe - Patients with any medical condition that, in the judgment of the investigator, might preclude safe completion of the study
Study is available at: John Umstead Hospital/Duke University
Butner, NC 27509
United States
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.